Eloxx Pharmaceuticals Management

Management criteria checks 1/4

Eloxx Pharmaceuticals' CEO is Sumit Aggarwal, appointed in Apr 2021, has a tenure of 1.67 years. total yearly compensation is $5.82M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth €13.34K. The average tenure of the management team and the board of directors is 1.7 years and 4.6 years respectively.

Key information

Sumit Aggarwal

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage	7.0%
CEO tenure	1.7yrs
CEO ownership	0.2%
Management average tenure	1.7yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sumit Aggarwal's remuneration changed compared to Eloxx Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$42m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$70m
Dec 31 2021	US$6m	US$408k	-US$67m

Compensation vs Market: Sumit's total compensation ($USD5.82M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Insufficient data to compare Sumit's compensation with company performance.

CEO

Sumit Aggarwal (49 yo)

1.7yrs

Tenure

US$5,824,041

Compensation

Mr. Sumit Aggarwal, MBA serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He is the President and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. since April 01, 2021. He ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sumit Aggarwal	President	1.7yrs	US$5.82m	0.23% € 13.3k
Daniel Geffken	Interim CFO	1.7yrs	US$130.75k	0% € 0
Vijay Modur	Head of Research & Development	1.7yrs	US$3.39m	0.18% € 10.5k
Barbara Ryan	Investor Relations Officer	no data	no data	no data
Ali Hariri	Chief Medical Officer	1.1yrs	no data	no data
Matthew Goddeeris	Vice President of Research	no data	no data	no data

1.7yrs

Average Tenure

54yo

Average Age

Experienced Management: 397's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sumit Aggarwal	President	1.7yrs	US$5.82m	0.23% € 13.3k
Tomer Kariv	Independent Chairman	6.2yrs	US$66.70k	0% € 0
Steven Rubin	Independent Director	5yrs	US$79.20k	0% € 0
Alan Walts	Independent Director	1.7yrs	US$252.28k	0.043% € 2.5k
Patrick Flume	Member of Medical Advisory Board	no data	no data	no data
Noreen Henig	Member of Medical Advisory Board	no data	no data	no data
David Bedwell	Member of Scientific Advisory Board	4.6yrs	no data	no data
Rachel Green	Member of Scientific Advisory Board	4.6yrs	no data	no data
Sudhir Kumar	Member of Scientific Advisory Board	4.6yrs	no data	no data
Lynne Maquat	Member of Scientific Advisory Board	4.6yrs	no data	no data
Donald Vandevanter	Member of Medical Advisory Board	no data	no data	no data
Christiane De Boeck	Member of Medical Advisory Board	no data	no data	no data

4.6yrs

Average Tenure

61yo

Average Age

Experienced Board: 397's board of directors are considered experienced (4.6 years average tenure).

Eloxx Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Recent updates

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced that it expects to receive $3.175 million in funding

Eloxx Pharmaceuticals, Inc. announced delayed 10-Q filing

Eloxx Pharmaceuticals, Inc. announced delayed annual 10-K filing

Nasdaq to Delist Common Stock of Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board

Eloxx Pharmaceuticals Receives a Determination Letter from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development

Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Nasdaq Grants Extension to Eloxx Pharmaceuticals to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

Eloxx Pharmaceuticals Receives Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives Written Notification Letter from the Listing Qualifications Department of Nasdaq

Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation

Eloxx Pharmaceuticals, Inc. Announces Committee Changes

Eloxx Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Eloxx Pharmaceuticals Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

COO, General Counsel & Corporate Secretary Neil Belloff has left the company

Executive Director of Finance & Accounting, Corporate Controller and Treasurer Gary Rakers has left the company

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell 3000E Index

Eloxx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $45.000001 million.

Independent Director has left the company

CEO & Director Gregory Williams has left the company

Founder & Director Silvia Noiman has left the company

VP of Finance & Accounting, Principal Financial & Accounting Officer and Treasurer has left the company

Eloxx Pharmaceuticals, Inc. Announces Resignation of Stephen Macdonald as Vice President, Finance and Accounting, and Treasurer (Principal Financial and Accounting Officer) Effective March 26, 2021

Eloxx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 11, 2021

The Cystic Fibrosis Foundation Awards upto $2 Million to Eloxx Pharmaceuticals Inc. for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations

New 90-day high: €4.46

Eloxx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €2.24

New 90-day low - €2.26

Eloxx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Eloxx Pharmaceuticals, Inc.(NasdaqGM:ELOX) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age